Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Xbrane Drops Keytruda Rival As It Pares Down Pipeline And Personnel
Swedish Biosimilars Developer Discloses ‘Unfortunately Necessary Measures’ To Cut Costs
Xbrane is aiming to achieve positive cash flow by Q1 2025 • Source: Shutterstock
More from Strategy
More from Business